As of 2026-03-18, the Intrinsic Value of Relmada Therapeutics Inc (RLMD) is -5.09 USD. This RLMD valuation is based on the model Peter Lynch Fair Value. With the current market price of 6.45 USD, the upside of Relmada Therapeutics Inc is -178.86%.
Based on its market price of 6.45 USD and our intrinsic valuation, Relmada Therapeutics Inc (RLMD) is overvalued by 178.86%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.09 - -5.09 | -5.09 | -178.86% |
| P/E | (10.93) - (16.48) | (15.82) | -345.3% |
| DDM - Stable | (8.90) - (52.83) | (30.86) | -578.5% |
| DDM - Multi | (8.47) - (40.34) | (14.13) | -319.1% |
| Market Cap (mil) | 356.15 |
| Beta | 1.88 |
| Outstanding shares (mil) | 55.22 |
| Enterprise Value (mil) | 354.77 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.87% |
| Cost of Debt | 5.00% |
| WACC | 6.27% |